Researchers assess the cost‐effectiveness of nivolumab plus ipilimumab vs lenvatinib or sorafenib for hepatocellular carcinoma from a US healthcare payer perspective.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/nivolumab-ipilimumab-not-cost-effective-liver-cancer-2026a10003mp?src=rss
Author :
Publish date : 2026-02-05 04:03:00
Copyright for syndicated content belongs to the linked Source.
